Champions Oncology Awarded $2 Million NCI Grant to Develop, Study Prostate Cancer Models

Champions Oncology Awarded $2 Million NCI Grant to Develop, Study Prostate Cancer Models
Champions Oncology has signed a $2 million competitive contract through the National Cancer Institute’s (NCI) Small Business Innovation Research (SBIR) program to build and study metastatic prostate cancer models derived from ethnically diverse patients. Fully characterized, ethnically diverse prostate cancer patient-derived xenograft (PDX) models are underrepresented among PDX banks, limiting opportunities for preclinical and translational oncology studies. In addition, both incidence and mortality rates of prostate cancer in African-American men are higher than in other groups. A primary objective of the project is to create new tools to better understand the ethnic disparities in prostate cancer. To achieve this, Champions partnered with InnoGenomics, a molecular diagnostics technology company, to apply their high-sensitivity liquid biopsy techniques to PDX models. The ethnically diverse prostate PDX models will be fully characterized and annotated. In addition to characterization of each model, Champions will also perform standard-of-care drug testing. The combined data will be then shared with the NCI to further prostate cancer research. "We are very excited that the NCI has chosen Champions for this SBIR award and has recognized Champions' expertise in quality management systems for commercializing the development of these models," Angela Davies, Champions’ chief medical officer, said in a
Subscribe or to access all post and page content.